Skip to main content

Cellyan Biotechnology Co., Ltd

corporate_fare Company Profile

Cellyan Biotechnology Co., Ltd

HKPD·NASDAQ·Trade & Services·CIK 0002007702

Cellyan Biotechnology Co., Ltd operates in two main business categories: OTC pharmaceutical cross-border e-commerce supply chain services and OTC pharmaceutical cross-border procurement and distribution. The Supply Chain Services division is primarily conducted through its Hong Kong subsidiary, Joint Cross Border. Joint Cross Border provides third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market. It connects OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, offering a one-stop solution for Mainland Chinese customers seeking cross-border OTC pharmaceutical products. These services include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the HKDOH, obtaining import and export permits and clearances, warehousing, packaging, and arranging logistics and end-to-end delivery. The Procurement and Distribution division is primarily conducted through its Hong Kong subsidiary, V-Alliance. Joint Cross Border addresses the complexities of cross-border OTC pharmaceutical regulations by offering a suite of supply chain solutions.

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 10 items for HKPD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for HKPD spans 6-K, 20-F, F-3, F-1.

Recent high-impact activity:

  • Cellyan Chairman and Independent Director Resign; CFO Joins Board, Chairman Seat Left Vacant
  • Shareholders Back 1-for-20 Reverse Split to Restore Nasdaq Compliance
  • Cellyan Biotechnology Proposes 1-for-20 Reverse Split to Regain Nasdaq Compliance
  • Cellyan Biotechnology 20-F Flags Going Concern Doubt, 34% Revenue Plunge, and Nasdaq Delisting Threat
  • Cellyan Biotechnology Secures Nasdaq Extension to January 2027 for $1 Bid Price Compliance; Reverse Split Under Consideration

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$13.43M
Net Income
-$1.14M
Diluted EPS
-$0.07
Op. Cash Flow
-$751.6K
Free Cash Flow
-$787.07K
Gross Profit
$1.39M
Operating Income
-$2.39M
Cash & Equivalents
$221.84K
Total Debt
$877.9K
Debt / Equity
0.09×
Net Margin
-8.5%
Source: 20-F · filed 2026-08-07 · accession 0001213900-26-086725

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 16,869 shares in HKPD as of the October 30, 2026 settlement, a 91.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 13, 2026, 83.3% of HKPD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,869 shares as of October 30, 2026
Change vs prior period▼ 91.4%
Days to cover1.00 at avg daily volume of 77,912
Daily short volume (FINRA facilities)83.3% of 2,138 shares on November 13, 2026
5-day average short volume63.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for HKPD, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.

1 shelf registrationreverse split

$200 Million Shelf Registration · Massive Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

HKPD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with H →
$1.58 -2.47% today
52-week range · as of 2026-11-12 $1.34 – $29
Market cap
$3.99M
Volume
8K (0.2× avg)
3-mo avg 43.2K
Live data · 2026-11-16 03:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HKPD - Latest Insights

HKPD
Nov 12, 2026, 9:57 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.58 info
Change: -$0.030 (-2%) info
Market Cap: $3.995M info
HKPD
Sep 23, 2026, 9:10 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.1222
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Sep 09, 2026, 8:55 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.1278
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Aug 07, 2026, 4:30 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.420
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Jul 16, 2026, 4:31 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5374
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Jun 12, 2026, 4:30 PM EDT
Filing Type: F-3
Importance Score:
9
Price at Filing: $0.420
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Mar 27, 2026, 3:19 PM EDT
Filing Type: F-1
Importance Score:
9
Price at Filing: $0.690
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Mar 26, 2026, 7:48 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.620
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Mar 18, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.640
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
HKPD
Jan 16, 2026, 4:29 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.7986
Real-time Price: $1.58 info
Change: Reverse Stock Split info
Market Cap: $3.995M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets